Drugs / SAAVI MVA-C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01418235 | Dec 2011 → Oct 2013 | — | HIV Vaccine Trials Network | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAAVI MVA-C | “SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid” NCT01418235 ↗ |
| Known as | MVA-C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01418235 ↗ |
| Modality | Vaccine | “SAAVI MVA-C is a recombinant modified vaccinia Ankara (MVA) vaccine” NCT01418235 ↗ |
| Route | Intramuscular | “SAAVI MVA-C administered as 0.5 ml intramuscularly” NCT01418235 ↗ |